The North America Infertility Diagnostics Devices Market is witnessing robust growth as infertility rates rise and awareness around reproductive health continues to improve. Infertility diagnostic devices play a crucial role in identifying underlying causes of male and female infertility, enabling timely clinical interventions and improving assisted reproductive outcomes. In 2025, the market was valued at USD 735.80 Million, and it is expected to grow at a CAGR of 7.40% from 2026 to 2035, reaching approximately USD 1,502.46 Million by 2035.

Market Growth Drivers

One of the primary factors driving market expansion is the increasing prevalence of infertility due to lifestyle changes, delayed parenthood, stress, obesity, and hormonal disorders. Rising awareness campaigns and educational initiatives by healthcare providers and fertility clinics have encouraged early diagnosis and treatment.

Supportive reimbursement policies in the United States and Canada have significantly improved access to fertility diagnostics, particularly for hormone testing, semen analysis, and imaging-based assessments. In addition, the growing acceptance of assisted reproductive technologies (ART), such as in vitro fertilization (IVF), has boosted demand for accurate and reliable diagnostic devices.

Technological Advancements in Infertility Diagnostics

Rapid advancements in diagnostic technologies are reshaping the infertility diagnostics landscape. Innovations such as automated semen analyzers, genetic screening tools, hormone analyzers, and embryo assessment systems have enhanced diagnostic precision and reduced turnaround time.

Digital imaging, AI-assisted analysis, and microfluidic technologies are increasingly being integrated into diagnostic devices, improving accuracy and clinical efficiency. These advancements are particularly valuable for fertility clinics and research laboratories seeking standardized and reproducible results.

Regional Market Insights

The United States dominates the North America infertility diagnostics devices market, supported by a strong network of fertility clinics, advanced healthcare infrastructure, and high adoption of ART procedures. Canada also contributes significantly, driven by increasing public awareness and growing investments in reproductive health services.

The region’s well-established regulatory framework and strong presence of diagnostic device manufacturers further support market growth.

Request a free sample report and explore the full table of contents today.

Competitive Landscape

Key players in the North America infertility diagnostics devices market are focusing on product innovation, strategic collaborations, and expanding their regional footprint. Prominent companies operating in this market include Cook Group; Vitrolife; Thermo Fisher Scientific; Hamilton Thorne LTD; Esco Micro Pte Ltd; Genea Limited; IVFtech APS; FUJIFILM Irvine Scientific; and The Baker Company Inc.